Grifols (GRFS) Non Operating Investment Income (2013 - 2014)

Grifols (GRFS) posted Non Operating Investment Income of $7.0 million for Q2 2013.

Grifols (GRFS) Non Operating Investment Income (2013 - 2014) Analysis & Trends

Grifols (GRFS) has reported Non Operating Investment Income for 1 consecutive years, with $7.0 million the latest figure, recorded in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	-
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	-
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	-
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	-
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	-
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	-
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	-
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Grifols	-	-	-	-

Download Data